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In the past, the clinical relevance of serum insulin
concentration has been minimal. Assessment of residual islet
beta cell function in diabetics relies on the measurement of C-
peptide rather than insulin. Measurement of insulin is clinically
important only for the detection of insulinomas and rare
genetic defects that lead to severe insulin resistance or
defective insulin secretion. The major value of determining
serum insulin levels is restricted to research studies
investigating the aetiology of type 2 diabetes and the metabolic
syndrome. However, in recent years pathology laboratories in
South Africa and elsewhere have seen an increase in the
number of requests for serum insulin measurements for the
assessment of insulin resistance using the HOMA (homeostasis
model assessment)1 and QUICKI (quantitative insulin
sensitivity check index)2 formulae. These formulae use fasting
insulin and glucose levels as a measure of insulin resistance.
The gold standard for assessing insulin resistance is the
euglycaemic, hyperinsulinaemic clamp method, a technique
not suited for use in a GP or specialist practice. The HOMA
and QUICKI methods are quicker, easier and cheaper to
perform and give results that have been shown to correlate
with data obtained from the clamp technique.1,2
Obesity and insulin resistance
The reason for the current trend of assessing insulin resistance
using the HOMA and QUICKI formulae may be related to the
high prevalence of obesity in South Africa3 and the increasing
demands made on physicians by patients who wish to lose
weight. Unfortunately, the strong association between insulin
resistance and obesity4,5 has been misinterpreted by some
health workers, who claim that insulin resistance causes
obesity. Insulin resistance is in fact a direct effect, and not a
cause, of obesity and is a physiological response to reduce
further weight gain.5 The main function of insulin within the
adipocyte is to inhibit triglyceride breakdown (lipolysis) and
therefore insulin resistance leads to increased lipolysis and a
slowing down of triglyceride deposition within the adipocytes.
This explains why insulin and sulphonylurea therapy lead to
weight gain, as does treatment of type 2 diabetes with the
thiazolidinedione families of insulin sensitisers.6,7 However the
biguanide, metformin, does not cause weight gain but rather
may induce modest weight loss.6 This seems to contradict the
statement that increased insulin sensitivity can lead to
increased weight gain. Recent studies, however, have shown
that the mechanism of action of metformin may not be due
entirely to its effects on insulin sensitivity. Rather, metformin
increases glucose clearance in an insulin-independent fashion.
Metformin acts by activating the intracellular enzyme
adenosine monophosphate (AMP)-activated protein kinase
(AMPK).8 This enzyme increases glucose uptake in a similar
fashion to insulin but independently of the hormone and also
reduces lipid synthesis,9 which may explain metformin’s ability
to induce some weight loss. Metformin has been used to treat
obesity, but its effects have been modest.10 A large clinical
study11 has shown that lifestyle intervention in conjunction
with dietary modification is far more effective than metformin
in preventing the onset of type 2 diabetes in obese subjects.
Furthermore, metformin has undesirable side-effects,
particularly gastro-intestinal effects and rarely lactic acidosis.6
Aetiology of obesity-associated insulin
resistance
How does obesity cause insulin resistance? Researchers and
clinicians have been attempting to answer this question for
many years, and the current opinion is that there are many
factors involved in the aetiology of obesity-related insulin
resistance. Primarily, the adipocyte is the source of a number of
factors that have been shown to effect insulin sensitivity. These
factors include free fatty acids, tumour necrosis factor alpha,
interleukin 6 and adiponectin.12 In addition, triglyceride
deposition within the muscle is increased in obese subjects and
the level of intramyocellular triglyceride has been shown to
correlate negatively with insulin sensitivity.13 Thus, there are
numerous clinical and in vitro studies demonstrating the ability
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of adipose tissue to increase insulin resistance.  Furthermore
obesity, via its ability to increase insulin resistance, is thought
to play a prime role in the aetiology of the metabolic
syndrome. This disorder is characterised by dyslipidaemia,
glucose intolerance, insulin resistance, hypertension and
abdominal obesity.14 However, the latest guidelines published
by the National Cholesterol Education Program (NCEP) for the
diagnosis of this syndrome recommend that insulin resistance
be assessed using fasting plasma glucose rather than fasting
serum insulin levels.15 This highlights the lack of clinical data
supporting the use of HOMA, QUICKI or insulin levels for
defining insulin resistance.    
Diagnosis and treatment of insulin
resistance
The measurement of insulin levels in obese subjects therefore
seems to have little clinical relevance. As already noted,
treating insulin resistance will not cause weight loss.
Furthermore, there exists no clinical or biochemical definition
of what constitutes an abnormal degree of insulin resistance.
Therefore, it is not known at what level of HOMA, QUICKI or
fasting insulin disease aetiology begins. A number of studies
have measured insulin resistance in the general population and
then defined cut-off points for the diagnosis of insulin
resistance. The cut-off points defined in these studies were the
25th centile of insulin sensitivity16,17 and the lower limit of the
95% confidence intervals for the QUICKI.18 These studies each
used a different method for measuring insulin sensitivity/
resistance and a different population group. These cut-off
points are therefore not universally applicable. Furthermore,
there is the question of what treatment should be used in the
case of insulin-resistant subjects. The biguanides and
thiazolidinediones are indicated for diabetic subjects only, and
all cause weight gain (with the exception of metformin).
Polycystic ovary disease (PCOS) is associated with increased
insulin resistance, but not necessarily obesity, and studies have
shown that treatment with insulin sensitisers does improve
fertility.19 This suggests that some disorders other than type 2
diabetes can be treated with insulin sensitisers. However, in the
case of the metabolic syndrome the best method for improving
insulin sensitivity remains weight loss. It has been shown that
even a modest loss in weight of 5 - 10% of current body mass
can have clinically significant effects on fasting insulin, glucose
and lipid levels as well as  blood pressure.20 Therefore, a safe
and effective alternative to the use of insulin sensitisers is
readily available. Unfortunately, long-term adherence to
lifestyle changes and diets is very difficult, often requiring
considerable input from a health care professional and total
commitment from the patient. This may explain why the
preferred method of treatment is the ‘magic’ pill. 
In conclusion, the measurement of insulin resistance in obese
subjects is not warranted. The co-morbid diseases associated
with obesity may rely on the presence of insulin resistance,14
but the insulin resistance is a result rather than a cause of high
body fat mass.5 Weight loss has clearly been shown to have
favourable effects on the metabolic dysfunction associated with
obesity20 and therefore it is the adiposity that should be the
prime target for both clinician and patient rather than the
insulin resistance. 
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Irritable bowel syndrome
IN BRIEF
Irritable bowel syndrome (IBS) is a cluster of symptoms without a recognised aetiopathology, but in which a variety of
different biological, psychological, and social factors can be implicated. Identification of meaningful subgroups of patients
within the syndrome is important as these groups may represent different aetiological and pathophysiological entities, and
they may require different treatment approaches. Using the gastro-intestinal symptoms together with rectal sensitivity and
psychological symptoms, researchers aimed to identify subgroups of IBS sufferers.They surmised that such groupings, which
cross conventional diagnostic approaches, might provide greater understanding of the pathogenesis of the condition.They
grouped 107 clinic patients with IBS according to physiological, physical and psychological parameters.All patients had severe
IBS and had failed to respond to usual medical treatment. Of the 107, 29 had predominantly diarrhoea and 26 predominantly
constipation, while 52 had alternating bowel habits.
Three subgroups were identified: Group I comprised patients with low distension thresholds and high rates of psychiatric
morbidity, doctor consultations, interpersonal problems, and sexual abuse. Group II also had low distension thresholds, but
low rates of childhood abuse and moderate levels of psychiatric disorders. Group III had high distension thresholds,
constipation or alternating IBS, and low rates of medical consultations and sexual abuse.
The report of the study in Gut (2003; 52: 1616-1622) concluded that the marked differences across the three groups
suggest that each may have a different pathogenesis and may respond to different treatment. Inclusion of psychosocial factors
in the analysis enabled more clinically meaningful groups to be identified than those traditionally determined by bowel
symptoms alone or together with rectal threshold.
